Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tiragolumab - Genentech

Next Previous
Drug Profile

Tiragolumab - Genentech

Alternative Names: anti-TIGIT - Roche; MTIG-7192A; RG-6058; RG6058-10; RG6058-11; RO 7092284

Latest Information Update: 28 Mar 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Genentech
  • Developer Chugai Pharmaceutical; Genentech; National Cancer Institute (USA); Roche; Washington University School of Medicine
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants; TIGIT protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued B-cell lymphoma; Cervical cancer; Gastric cancer; Liver cancer; Malignant melanoma; Multiple myeloma; Non-small cell lung cancer; Oesophageal cancer; Rectal cancer; Renal cell carcinoma; Small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer

Most Recent Events

  • 05 Mar 2025 Roche completes a phase II trial in Non-small cell lung cancer (Adjuvant therapy, Combination therapy, First-line therapy, Late-stage disease, Neoadjuvant therapy) in USA, Switzerland, Australia, Italy, Netherlands, Poland, South Korea, Spain (IV) (NCT04832854)
  • 27 Feb 2025 Chugai Pharmaceutical and Roche plans to submit a sBLA for tiragolumab for Non small cell lung cancer (Combination therapy) in Japan in 2025 (Chugai Pharmaceutical pipeline, February 2025)
  • 27 Feb 2025 Chugai Pharmaceutical and Roche plans to submit an sBLA for tiragolumab for Esophageal cancer (Combination therapy with Tecentriq) in Japan in 2025 (Chugai Pharmaceutical pipeline, February 2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top